Polianta Ltd continued to hold its stake in Express Scripts Holding Company (NASDAQ:ESRX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,900 shares of the company’s stock at the end of the second quarter. Polianta Ltd’s holdings in Express Scripts Holding were worth $951,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Hancock Holding Co. raised its position in shares of Express Scripts Holding by 9.9% in the first quarter. Hancock Holding Co. now owns 183,489 shares of the company’s stock valued at $12,094,000 after buying an additional 16,536 shares during the last quarter. Van ECK Associates Corp raised its position in shares of Express Scripts Holding by 28.8% in the first quarter. Van ECK Associates Corp now owns 373,636 shares of the company’s stock valued at $24,626,000 after buying an additional 83,568 shares during the last quarter. Twin Capital Management Inc. raised its position in shares of Express Scripts Holding by 0.8% in the first quarter. Twin Capital Management Inc. now owns 46,560 shares of the company’s stock valued at $3,069,000 after buying an additional 360 shares during the last quarter. Wilkins Investment Counsel Inc. raised its position in shares of Express Scripts Holding by 6.9% in the first quarter. Wilkins Investment Counsel Inc. now owns 118,336 shares of the company’s stock valued at $7,800,000 after buying an additional 7,630 shares during the last quarter. Finally, ACR Alpine Capital Research LLC raised its position in shares of Express Scripts Holding by 6.3% in the first quarter. ACR Alpine Capital Research LLC now owns 1,463,799 shares of the company’s stock valued at $96,479,000 after buying an additional 87,292 shares during the last quarter. 90.24% of the stock is currently owned by hedge funds and other institutional investors.

Express Scripts Holding Company (NASDAQ:ESRX) traded up 0.83% during midday trading on Wednesday, hitting $62.24. 792,868 shares of the stock were exchanged. The company has a market capitalization of $35.95 billion, a P/E ratio of 10.80 and a beta of 0.90. The company’s 50 day moving average is $62.51 and its 200 day moving average is $64.30. Express Scripts Holding Company has a 1-year low of $57.80 and a 1-year high of $77.61.

Express Scripts Holding (NASDAQ:ESRX) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.71 by $0.02. Express Scripts Holding had a return on equity of 25.58% and a net margin of 3.50%. The company had revenue of $25.35 billion during the quarter, compared to analyst estimates of $25.52 billion. During the same quarter in the previous year, the firm earned $1.57 earnings per share. Express Scripts Holding’s revenue was up .5% on a year-over-year basis. Analysts predict that Express Scripts Holding Company will post $6.99 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/16/polianta-ltd-has-951000-position-in-express-scripts-holding-company-esrx.html.

Several equities analysts have recently weighed in on the stock. Bank of America Corporation reissued a “neutral” rating and issued a $77.00 price objective on shares of Express Scripts Holding in a research report on Tuesday, April 25th. Cowen and Company dropped their price objective on shares of Express Scripts Holding from $90.00 to $83.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 25th. SunTrust Banks, Inc. reissued a “buy” rating on shares of Express Scripts Holding in a research report on Tuesday, April 25th. Mizuho dropped their price objective on shares of Express Scripts Holding from $76.00 to $61.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 25th. Finally, UBS AG set a $71.00 price objective on shares of Express Scripts Holding and gave the company a “hold” rating in a research report on Tuesday, April 25th. Four research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $71.17.

In other news, VP Phyllis S. Anderson sold 1,100 shares of the business’s stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $60.08, for a total transaction of $66,088.00. Following the completion of the transaction, the vice president now owns 11,108 shares of the company’s stock, valued at $667,368.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.68% of the stock is currently owned by insiders.

Express Scripts Holding Company Profile

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Want to see what other hedge funds are holding ESRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Express Scripts Holding Company (NASDAQ:ESRX).

Institutional Ownership by Quarter for Express Scripts Holding (NASDAQ:ESRX)

Receive News & Stock Ratings for Express Scripts Holding Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts Holding Company and related stocks with our FREE daily email newsletter.